These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 36020)

  • 21. [Therapeutic strategies in Parkinson's disease].
    Shoulson I
    Arch Neurobiol (Madr); 1991; 54(6):277-81. PubMed ID: 1687429
    [No Abstract]   [Full Text] [Related]  

  • 22. Does treatment with dopamine agonists affect utilization of exogenous levodopa in the parkinsonian striatum?
    Melamed E
    J Neural Transm Suppl; 1995; 45():57-60. PubMed ID: 8748609
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Functional organization of the basal ganglia: therapeutic implications for Parkinson's disease.
    Obeso JA; Rodríguez-Oroz MC; Benitez-Temino B; Blesa FJ; Guridi J; Marin C; Rodriguez M
    Mov Disord; 2008; 23 Suppl 3():S548-59. PubMed ID: 18781672
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Dopamine-receptor stimulants in the treatment of Parkinson's disease (author's transl)].
    Ringwald E; Hirt D; Markstein R; Vigouret JM
    Nervenarzt; 1982 Feb; 53(2):67-71. PubMed ID: 7063089
    [No Abstract]   [Full Text] [Related]  

  • 25. Dopaminergic neuroprotection and regeneration by neurturin assessed by using behavioral, biochemical and histochemical measurements in a model of progressive Parkinson's disease.
    Oiwa Y; Yoshimura R; Nakai K; Itakura T
    Brain Res; 2002 Aug; 947(2):271-83. PubMed ID: 12176170
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Medications for Parkinson's disease.
    Whitney CM
    Neurologist; 2007 Nov; 13(6):387-8. PubMed ID: 18090719
    [No Abstract]   [Full Text] [Related]  

  • 27. Developments in understanding the physiology and pharmacology of parkinsonism.
    Teräväinen H; Calne DB
    Acta Neurol Scand; 1979 Jul; 60(1):1-11. PubMed ID: 40381
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Striatal alpha6* nicotinic acetylcholine receptors: potential targets for Parkinson's disease therapy.
    Quik M; McIntosh JM
    J Pharmacol Exp Ther; 2006 Feb; 316(2):481-9. PubMed ID: 16210393
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel insights in pharmacogenetics of drug response in Parkinson's disease.
    Arbouw ME; Guchelaar HJ; Egberts TC
    Pharmacogenomics; 2010 Feb; 11(2):127-9. PubMed ID: 20136351
    [No Abstract]   [Full Text] [Related]  

  • 30. Presynaptic dopamine receptors in striatal nerve endings: absence of haloperidol-induced supersensitivity.
    Raiteri M; Cerrito F; Casazza G; Levi G
    Adv Biochem Psychopharmacol; 1980; 24():37-43. PubMed ID: 7405669
    [No Abstract]   [Full Text] [Related]  

  • 31. Implanted reuptake-deficient or wild-type dopaminergic neurons improve ON L-dopa dyskinesias without OFF-dyskinesias in a rat model of Parkinson's disease.
    Vinuela A; Hallett PJ; Reske-Nielsen C; Patterson M; Sotnikova TD; Caron MG; Gainetdinov RR; Isacson O
    Brain; 2008 Dec; 131(Pt 12):3361-79. PubMed ID: 18988638
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The catecholamines.
    Iversen LL
    Nature; 1967 Apr; 214(5083):8-14. PubMed ID: 6033340
    [No Abstract]   [Full Text] [Related]  

  • 33. Pharmacology of Parkinson's disease.
    Burton K; Calne DB
    Neurol Clin; 1984 Aug; 2(3):461-72. PubMed ID: 6152482
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Levodopa-induced changes in synaptic dopamine in patients with Parkinson's disease as measured by [11C]raclopride displacement and PET.
    Tedroff J; Pedersen M; Aquilonius SM; Hartvig P; Jacobsson G; Långström B
    Neurology; 1996 May; 46(5):1430-6. PubMed ID: 8628494
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dysfunction of dopamine homeostasis: clues in the hunt for novel Parkinson's disease therapies.
    Bisaglia M; Greggio E; Beltramini M; Bubacco L
    FASEB J; 2013 Jun; 27(6):2101-10. PubMed ID: 23463698
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Physiology and pharmacology of dopamine D2-receptors: their implications in dopamine-substitute therapy for Parkinson's disease.
    Mercuri NB; Calabresi P; Bernardi G
    Neurology; 1989 Aug; 39(8):1106-8. PubMed ID: 2569697
    [No Abstract]   [Full Text] [Related]  

  • 37. Short review on monoamine oxidase and its inhibitors.
    Kanazawa I
    Eur Neurol; 1994; 34 Suppl 3():36-9. PubMed ID: 7821334
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Catecholamines.
    Axelrod J; Weinshilboum R
    N Engl J Med; 1972 Aug; 287(5):237-42. PubMed ID: 4402575
    [No Abstract]   [Full Text] [Related]  

  • 39. [Dopamine agonists in the therapy of parkinson syndrome].
    Kapfhammer HP; Rüther E
    Nervenarzt; 1985 Feb; 56(2):69-81. PubMed ID: 3982566
    [No Abstract]   [Full Text] [Related]  

  • 40. Molecular basis of dopamine replacement therapy and its side effects in Parkinson's disease.
    You H; Mariani LL; Mangone G; Le Febvre de Nailly D; Charbonnier-Beaupel F; Corvol JC
    Cell Tissue Res; 2018 Jul; 373(1):111-135. PubMed ID: 29516217
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.